Filing Flows › Standard Biotools (LAB) › Q3 2026
Standard Biotools (LAB) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 3, 2026
Standard Biotools (LAB) reported revenue of $19.4M for the third quarter 2026 (Q3 2026), -0.9% from a year earlier and -4% from the quarter before. Operating margin was -102.0%, net earnings $13.5M (69.6% of revenue).
Standard Biotools, Q3 2026: revenue $19.4M (-0.9% year over year), operating margin -102.0%, net earnings $13.5M, operating cash flow −$6.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.4M | -4% | -0.9% |
| Operating profit | −$19.8M | — | — |
| Net earnings | $13.5M | — | — |
| Operating cash flow | −$6.2M | — | — |
What changed
Revenue was $19.4M in Q3 2026, down 1% year over year and down 4% from the previous quarter. Consumables was the largest line at 43% of revenue. Services and Other Revenue lost $695K year over year (down 12%), 416% of the total change.
Gross margin was 55.9%, up 7.4 points from Q3 2025. Operating costs exceeded revenue by $19.8M, an operating margin of -102.0%. Operating expenses fell 28% while revenue fell 1%. The fastest-growing cost line was Other operating costs (+23%). Net earnings were $13.5M. The effective tax rate was 0.2%. Non-operating items added $33.3M, 246% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$6.2M. Non-cash charges added back $1.2M of depreciation and amortization and $3.7M of share-based compensation. Working capital and other items used $24.6M.
Questions
What was Standard Biotools' revenue in the third quarter 2026?
Standard Biotools (LAB) reported revenue of $19.4M for the third quarter 2026 (Q3 2026), -0.9% from a year earlier and -4% from the quarter before.
Was Standard Biotools profitable in the third quarter 2026?
Operating loss was $19.8M (-102.0% of revenue) and net earnings $13.5M.
Source: Standard Biotools 10-Q on SEC EDGAR.